CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Peptomyc S.L. is developing a novel cancer therapy using anti-Myc peptides, targeting a common oncogene in various cancers. Their lead product, OMO-101, aims to demonstrate safety and efficacy in glioblastoma patients during clinical trials.
Peptomyc S.L. is an SME created to develop a new, first-in-class, cancer therapy using innovative anti-Myc peptides.
Myc is an oncogene deregulated in the majority of human cancers, making Peptomyc’s products potentially applicable to all cancer patients.
The recombinant peptides are based on Omomyc, a Myc inhibitor benefiting from 20 years of preclinical validation as gene therapy.
Omomyc displays remarkable therapeutic impact in multiple cancer models, with limited side effects, and no emergen…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
